149 related articles for article (PubMed ID: 12196435)
1. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.
Korytkowski M; Thomas A; Reid L; Tedesco MB; Gooding WE; Gerich J
Diabetes Care; 2002 Sep; 25(9):1607-11. PubMed ID: 12196435
[TBL] [Abstract][Full Text] [Related]
2. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
3. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
Rizzo MR; Barbieri M; Grella R; Passariello N; Barone M; Paolisso G
Diabetes Metab; 2004 Feb; 30(1):81-9. PubMed ID: 15029102
[TBL] [Abstract][Full Text] [Related]
5. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
Moon JS; Ha KS; Yoon JS; Lee HW; Lee HC; Won KC;
Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
[TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
Ravikumar B; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
[TBL] [Abstract][Full Text] [Related]
8. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
9. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
Riddle MC; Schneider J
Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
[TBL] [Abstract][Full Text] [Related]
10. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
[TBL] [Abstract][Full Text] [Related]
11. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
[TBL] [Abstract][Full Text] [Related]
12. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes.
Overkamp D; Volk A; Maerker E; Heide PE; Wahl HG; Rett K; Häring HU
Diabetes Care; 2002 Nov; 25(11):2065-73. PubMed ID: 12401758
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
14. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Diabet Med; 2014 Dec; 31(12):1515-23. PubMed ID: 24824633
[TBL] [Abstract][Full Text] [Related]
15. Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes.
Yokoyama H; Sone H; Yamada D; Honjo J; Haneda M
Diabetes Res Clin Pract; 2011 Feb; 91(2):148-53. PubMed ID: 21067837
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactive insulin response to a single dose of glimepiride in lean type 2 diabetic subjects.
Singh J; Unnikrishnan AG; Agrawal NK; Singh SK; Agrawal JK
J Assoc Physicians India; 2002 Oct; 50():1232-5. PubMed ID: 12568204
[TBL] [Abstract][Full Text] [Related]
17. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
[TBL] [Abstract][Full Text] [Related]
18. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Ligtenberg JJ; Reitsma WD; van Haeften TW
Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
[TBL] [Abstract][Full Text] [Related]
19. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus.
Kabadi MU; Kabadi UM
Clin Ther; 2004 Jan; 26(1):63-9. PubMed ID: 14996518
[TBL] [Abstract][Full Text] [Related]
20. The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus.
Pfützner A; Lorra B; Abdollahnia MR; Kann PH; Mathieu D; Pehnert C; Oligschleger C; Kaiser M; Forst T
Diabetes Technol Ther; 2006 Jun; 8(3):375-84. PubMed ID: 16800759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
